As a postdoctoral research fellow at the University of Michigan, I am dedicated to pioneering research endeavors aimed at advancing therapeutic strategies for prostate cancer. Collaborating within a multidisciplinary team of esteemed researchers, clinicians, and stakeholders, my focus lies in elucidating novel therapeutic modalities to address the complexities of this disease and enhance patient outcomes. With a robust background in molecular biology, therapeutics, and preclinical drug screening, complemented by my medical doctor institutional license and extensive experience as a freelance translator, I bring a diverse skill set to the table. My doctoral studies in Oncology at Jilin University have equipped me with a profound understanding of cancer epigenetics, evidenced by numerous publications and accolades. Eager to forge collaborations with fellow experts in the field, I am committed to contributing to the advancement of scientific knowledge and the improvement of patient care within the realm of prostate cancer research.

Qiao Y*, Wotring JW*, Zheng Y*, Zhang CJ, Zhang Y, Jiang X, Pretto CD, Eyunni S, Parolia A, He T, Cheng C, Cao X, Wang R, Su F, Ellison SJ, Wang Y, Qin J, Yan H, Zhou Q, Ma L, Sexton JZ, Chinnaiyan AM. Proxalutamide reduces SARS-CoV-2 infection and associated inflammatory response. Proc Natl Acad Sci U S A, 2023 (co-first)

Yang Zheng, Zhihong Wang, Simeng Wei, Ziling Liu, Guojiang Chen. Epigenetic silencing of chemokine CCL2 represses macrophage infiltration to potentiate tumor development in small cell lung cancer. Cancer Letters, 2020.

Yang Zheng, Lili Tang, Guojiang Chen, Ziling Liu. Comprehensive bioinformatics analysis of key methyltransferases and demethylases for histone lysines in hepatocellular carcinoma. Technology in Cancer Research & Treatment, 2020.

Yang Zheng, Lili Tang, Ziling Liu. Multi-omics analysis of an immune-based prognostic predictor in non-small cell lung cancer. BMC Cancer, 2021.